Salvage therapy for primary central nervous system lymphoma with (90)Y-Ibritumomab and Temozolomide.

Abstract

Aggressive initial treatment of Primary Central Nervous System Lymphoma (PCNSL) has achieved prolonged survival and occasional cures. However, some patients do not respond to initial therapy and others relapse after an initial remission. The optimal salvage regimen is not known and many different strategies have been proposed. In this report we describe the efficacy of a combination of (90)Y-Ibritumomab Tiuxetan (Zevalin) and Temozolamide as a maintenance therapy for recurrent PCNS Lymphoma in two patients that are both alive and in complete remission after 9 and 10 months respectively. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.

• Authors: Vincenzo Pitini, Sergio Baldari, Giuseppe Altavilla, Carmela Arrigo, Claudia Naro, Francesca Perniciaro
• Journal: Journal of neuro-oncology (J Neurooncol) Vol. 83 Issue 3 Pg. 291-3 (Jul 2007) ISSN: 0167-594X [Print] United States
• PMID: 17245621 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antineoplastic Agents, Alkylating
• Yttrium Radioisotopes
• ibritumomab tiuxetan
• Dacarbazine
• Temozolomide

Topics

• Aged
• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Agents, Alkylating (therapeutic use)
• Brain Neoplasms (drug therapy, radiotherapy, therapy)
• Combined Modality Therapy
• Dacarbazine (analogs & derivatives, therapeutic use)
• Disease-Free Survival
• Female
• Humans
• Lymphoma (drug therapy, radiotherapy, therapy)
• Magnetic Resonance Imaging
• Middle Aged
• Neoplasm Recurrence, Local (drug therapy, radiotherapy, therapy)
• Radioimmunotherapy
• Remission Induction
• Salvage Therapy
• Survival Rate
• Temozolomide
• Yttrium Radioisotopes (therapeutic use)